We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
This competition aims to honour those with exceptional talent within the medical and scientific industry, by offering a platform for candidates to share best practice and prove they’ve got the skills to be successful.
Milestone Pharmaceuticals announced positive data from its Phase 2 NODE-1 trial evaluating etripamil, for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a potentially debilitating cardiac arrhythmia.